// App-Quantinova.ai

: Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Researchers

Presenter

  • Jennifer O'Sullivan

Principal Investigators

  • Angela Hamblin

  • Anesh Panchal

  • Christina Yap

  • Sonia Fox

  • Samah Alimam

  • Helene Marie-Pierre Dreau

  • Kieran Howard

  • Pauline Ware

  • Samantha Baker

  • Nicholas C.P. Cross

  • Mary Frances McMullin

  • Claire N. Harrison

  • Adam J. Mead

Medical Centers

  • MRC Molecular Haematology Unit, University of Oxford, Oxford, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, University of Oxford, Oxford, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham, GBR

  • Haematology Department, 4th Floor Southwark Wing, London, United Kingdom

  • Dept of Haematology, Oxford University Hospitals NHS Foundation Trust

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Wessex Regional Genetics Laboratory,Salisbury NHS Foundation Trust,Salisbury,United Kingdom

  • University of Southampton, United Kingdom.

  • Queen's University Belfast, Belfast, United Kingdom

  • Department of Virology, Royal Free Hospital, London, United Kingdom

  • MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Essential thrombocythemia

  • Acute Leukemia

Biomarkers

  • Tet methylcytosine dioxygenase 2

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • Hydroxycarbamide

  • Ruxolitinib phosphate

  • Interferon

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved